Zobrazeno 1 - 10
of 103
pro vyhledávání: '"Eisaku Miyauchi"'
Autor:
Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi, Tomohiro Sakakibara, Toshiyuki Harada, Kazuhiro Usui, Akira Inoue, Shunichi Sugawara
Publikováno v:
Thoracic Cancer, Vol 14, Iss 27, Pp 2804-2810 (2023)
Abstract Background This phase II trial was designed to evaluate the efficacy and safety of S‐1 combined with weekly irinotecan as a second‐ or third‐line treatment for patients with advanced or recurrent squamous cell lung cancer. Methods Pati
Externí odkaz:
https://doaj.org/article/7762f015da734d1f801fd33d7a6edbc5
Autor:
Yasunori Murata, MD, PhD, Shigeru Tanzawa, MD, PhD, Toshihiro Misumi, PhD, Hiroshige Yoshioka, MD, PhD, Eisaku Miyauchi, MD, PhD, Kiichiro Ninomiya, MD, PhD, Masafumi Takeshita, MD, PhD, Kensaku Ito, MD, PhD, Tatsuro Okamoto, MD, PhD, Shunichi Sugawara, MD, PhD, Yosuke Kawashima, MD, Kazuki Hashimoto, MD, Masahide Mori, MD, PhD, Akihiko Miyanaga, MD, PhD, Anna Hayashi, MD, Hisashi Tanaka, MD, PhD, Ryoichi Honda, MD, PhD, Masafumi Nojiri, MD, PhD, Yuki Sato, MD, Akito Hata, MD, Ken Masuda, MD, PhD, Toshiyuki Kozuki, MD, PhD, Takahisa Kawamura, MD, PhD, Takuji Suzuki, MD, PhD, Teppei Yamaguchi, MD, PhD, Kazuhiro Asada, MD, PhD, Satoshi Tetsumoto, MD, PhD, Hiroshi Tanaka, MD, PhD, Satoshi Watanabe, MD, PhD, Yukihiro Umeda, MD, PhD, Kakuhiro Yamaguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Kosuke Tsuruno, MD, PhD, Yuki Misumi, MD, PhD, Hiroshi Kuraishi, MD, PhD, Ken Yoshihara, MD, PhD, Akira Nakao, MD, PhD, Akihito Kubo, MD, PhD, Toshihiko Yokoyama, MD, PhD, Kana Watanabe, MD, PhD, Nobuhiko Seki, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100593- (2023)
Introduction: Necitumumab plus gemcitabine and cisplatin (GCN) is a standard therapy for patients with advanced lung squamous cell carcinoma (LSqCC). However, the efficacy and tolerability of GCN in second-line or later treatment for patients previou
Externí odkaz:
https://doaj.org/article/0e1d4e104d1e4f01bd75edf40b9e925c
Autor:
Hidekazu Shirota, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Hiroshi Tada, Muneaki Shimada, Tetsuya Niihori, Yoko Aoki, Ikuko Sugiyama, Maako Kawamura, Jun Yasuda, Shuhei Suzuki, Takeshi Iwaya, Motonobu Saito, Tsuyoshi Saito, Hiroyuki Shibata, Toru Furukawa, Chikashi Ishioka
Publikováno v:
Cancer Medicine, Vol 12, Iss 5, Pp 6170-6181 (2023)
Abstract Background A paradigm shift has occurred in cancer chemotherapy from tumor‐specific treatment with cytotoxic agents to personalized medicine with molecular‐targeted drugs. Thus, it is essential to identify genomic alterations and molecul
Externí odkaz:
https://doaj.org/article/8a80aeda87b14dc480de839989bfda14
Autor:
Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, Yukari Uemura, Eisaku Miyauchi, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Keiichi Jingu, Hisatoshi Sugiura
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 37, Iss , Pp 57-63 (2022)
Purpose: Intensity-modulated radiotherapy (IMRT) is currently used more commonly than 3-dimensional conformal radiation for definitive thoracic radiation. We examined the efficacy profiles of concurrent chemoradiotherapy (CCRT) with IMRT after durval
Externí odkaz:
https://doaj.org/article/50d03165c0224d01824af0e40ec388da
Autor:
Hisashi Tanaka, Hiroaki Sakamoto, Takahiro Akita, Fumiyoshi Ohyanagi, Yosuke Kawashima, Yuichi Tambo, Azusa Tanimoto, Atsushi Horiike, Eisaku Miyauchi, Yuko Tsuchiya‐Kawano, Noriko Yanagitani, Makoto Nishio
Publikováno v:
Thoracic Cancer, Vol 13, Iss 10, Pp 1471-1478 (2022)
Abstract Background Dacomitinib is the second‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs are often re‐administered in Japan after the disease p
Externí odkaz:
https://doaj.org/article/5e5f715847fd4a66aa35dd6d0e976bda
Autor:
Takaya Yamamoto, Yoko Tsukita, Yu Katagiri, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Eisaku Miyauchi, Ryota Saito, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background In clinical practice, the effect of durvalumab and radiation pneumonitis (RP) on survival after intensity-modulated radiotherapy (IMRT) is not fully understood. The purpose of this retrospective study was to investigate factors re
Externí odkaz:
https://doaj.org/article/0afaa25fb41c4de5922771f6af97c0ef
Autor:
Koji Murakami, Tsutomu Tamada, Daisuke Saigusa, Eisaku Miyauchi, Masayuki Nara, Masakazu Ichinose, Makoto Kurano, Yutaka Yatomi, Hisatoshi Sugiura
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Since the clinical outcome of patients with sarcoidosis is still unpredictable, a good prognostic biomarker is necessary. Autotaxin (ATX) and phosphatidylserine-specific phospholipase A1 (PS-PLA1) function as main enzymes to produce lysophos
Externí odkaz:
https://doaj.org/article/3282150208ff44bdbd9b41e96e062af3
Autor:
Kana Watanabe, Ryota Saito, Eisaku Miyauchi, Hiromi Nagashima, Atsushi Nakamura, Shunichi Sugawara, Nobuyuki Tanaka, Hiroshi Terasaki, Tatsuro Fukuhara, Makoto Maemondo
Publikováno v:
Cancers, Vol 15, Iss 17, p 4231 (2023)
Background: Osimertinib was first approved for the treatment of non-small cell lung cancer (NSCLC) in patients who have developed the epidermal growth factor receptor (EGFR) T790M mutation after treatment with EGFR tyrosine kinase inhibitors (TKIs).
Externí odkaz:
https://doaj.org/article/51224864e06f4072be6e5ed8c791e226
Autor:
Eisaku Miyauchi, Hisashi Tanaka, Atsushi Nakamura, Toshiyuki Harada, Taku Nakagawa, Mami Morita, Daisuke Jingu, Tomoya Kuda, Shunichi Gamou, Ryota Saito, Akira Inoue
Publikováno v:
Thoracic Cancer, Vol 12, Iss 21, Pp 2886-2893 (2021)
Abstract Background NJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin‐bound paclitaxel (nab‐PTX) in patients with advanced non‐small cell lung cancer (NSCLC). Methods The study included patients aged ≥20 years with
Externí odkaz:
https://doaj.org/article/1d2e818515ca48b8833458e79cf91807
Autor:
Kotaro Abe, Masahiko Kanehira, Shinya Ohkouchi, Sakiko Kumata, Yamato Suzuki, Hisashi Oishi, Masafumi Noda, Akira Sakurada, Eisaku Miyauchi, Tohru Fujiwara, Hideo Harigae, Yoshinori Okada
Publikováno v:
Cancer Medicine, Vol 10, Iss 9, Pp 3085-3100 (2021)
Abstract Lung cancer is the most common cause of cancer‐related death in developed countries; therefore, the generation of effective targeted therapeutic regimens is essential. Recently, gene therapy approaches toward malignant cells have emerged a
Externí odkaz:
https://doaj.org/article/b3d8741dee05493d9acc6d789ba45bb3